COVID-19 antidote VINCOV-19 ready for Phase-3 trials, market authorization
Phasetwo clinical trials were conducted across multiple centers in India and included further than 200 cases.
The University of Hyderabad( UoH), in collaboration with the Center for CSIR- Cellular Molecular Biology( CCMB) and VINS Bio products Limited( a Hyderabad- grounded leading immunological company), blazoned the successful completion of the Phase- two clinical trials of VINCOV- 19, India’s first cure and a cure against SARS- CoV- 2 contagion.
According to reports, VINCOV- 19 is now ready for contemporaneous phase- three clinical trials and request authorization.
expensive and a safer than a formula feed.
VINCOV- 19 contains Equine polyclonal antibodies( EpAbs) against the Covid- 19 contagion. It comprises largely purified F( ab ’) 2 antibody fractions that have a high neutralizing capacity against the SARS- CoV- 2 contagion.
About phase- two clinical trials
Phase two clinical trials were conducted across multiple centers in India and included further than 200 cases. also, it included testing the cure against the Omicron variant to insure maximum content against the contagion and its given mutations.
In this phase, VINCOV- 19 was administered to cases with moderate inflexibility of COVID- 19. One group of cases was given VINCOV- 19 along with Standard of Care( SoC), while another group was given SoC only.
The cure showed a good safety profile in the Phase- two trials. Also, there was an early enhancement in the clinical condition of the cases administered VINCOV- 19.
The Phase- 2 clinical trials were completed in September 2022.
VinayK. Nandicoori’s statement
VinayK. Nandicoori, Director, CSIR- CCMB, said, “ These remedial antibodies are the first in India and among the many around the globe. It's essential to have multiple options, including remedial antibodies, especially for severe clinical cases of COVID. It's a major step for the future targeted collaborations between academia and assiduity. ”
Siddharth Daga’s statement
Siddharth Daga, Chief Executive Officer, of VINS Bio products Limited, said, “ Phase- 2 clinical trials of VINCOV- 19 have been veritably successful. VINCOV- 19 has been shown to be safe and ensures the speedy recovery of cases suffering from COVID- 19. The development of VINCOV- 19 by VINS Bio is an protestation of “ Aatmanirbhar Bharat ” and the collaboration between the three mates is a step in the right direction. We'd prompt the authorities to allow us the request authorization so that we can strengthen our fight against COVID- 19. ”